HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") "Silence and Replace" platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offering of 900,000 shares of its common stock with long-term investor Suvretta Capital. Each share of common stock is being sold at an offering price of $13.00 and each pre-funded warra

-Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Clinically Significant Improvements in Swallowing Function Achieved 3-months Post-Treatment with BB-301 for Subject 3, with Subject 3 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Symptom Burden- -Positive Interim Clinical Study Results

HAYWARD, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming conferences. TD Cowen 45th Annual Health Care ConferenceDate: March 5, 2025Time of Presentation: 9:50 AM to 10:20 AM EST Format: Presentation & 1x1 Meetings The Benitec presentation will also be available via live webcast here. Leerink Partners Global Healthcare Conference 2025Date: March 12

-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024. The Company has filed its

HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced the acceptance of a late-breaking oral abstract for the BB-301 Phase 1b/2a Clinical Treatment Study ongoing in Subjects diagnosed with Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagia. Interim clinical study updates for the first three Subjects will be discussed in an oral presentation at the Muscular Dystrophy Association Clinical and Scientific Confere

HAYWARD, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming conferences. Muscular Dystrophy Association Gene Therapy SummitDates: January 28 – 30, 2025Location: Tucson, AZ Guggenheim SMID Cap Biotech ConferenceDate: February 5, 2025Location: New York, NYFormat: 1x1 Meetings Oppenheimer 35th Annual Healthcare Life Sciences Conference (being held virtu

HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming investor conferences. Piper Sandler Annual Healthcare ConferenceDate: December 4, 2024Time of Fireside Discussion: 12:00 PM ESTLocation: New York, NYFormat: Fireside Discussion & 1x1 Meetings The Benitec presentation will also be available via live webcast here. Oppenheimer Movers in Rare Disease

-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29th Annual Congress of the World Muscle Society- -Third Subject Safely Treated with the Low-Dose of BB-301 in October 2024, and Fourth Subject Expected to Receive Treatment with the Low-Dose of BB-301 in December 2024 HAYWARD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing no

HAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024. Date: November 11, 2024Time: 2:30 PMFormat: Fireside Chat & 1x1 Meetings The Benitec presentation will also be available via live webcast here. Please contact your Guggenheim representative to schedule a 1x1 me

-Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been revised from the conference call information provided on October 12th- HAYWARD, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces updated webcast information to discuss the interim clinical study data previously reported on Saturday,

H.C. Wainwright initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $28.00

Robert W. Baird initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $30.00

Oppenheimer initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $35.00

Guggenheim initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $17.00

Leerink Partners initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $13.00

Piper Sandler initiated coverage of Benitec Biopharma with a rating of Overweight and set a new price target of $30.00

HC Wainwright & Co. initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $10.00

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

3 - Benitec Biopharma Inc. (0001808898) (Issuer)

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

4 - Benitec Biopharma Inc. (0001808898) (Issuer)

424B5 - Benitec Biopharma Inc. (0001808898) (Filer)

8-K - Benitec Biopharma Inc. (0001808898) (Filer)

8-K - Benitec Biopharma Inc. (0001808898) (Filer)

8-K - Benitec Biopharma Inc. (0001808898) (Filer)

SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

8-K - Benitec Biopharma Inc. (0001808898) (Filer)

10-Q - Benitec Biopharma Inc. (0001808898) (Filer)

SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

SCHEDULE 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

8-K/A - Benitec Biopharma Inc. (0001808898) (Filer)

HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025- HAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its second fiscal quarter ended December 31, 2024. The Company has filed its

-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29th Annual Congress of the World Muscle Society- -Third Subject Safely Treated with the Low-Dose of BB-301 in October 2024, and Fourth Subject Expected to Receive Treatment with the Low-Dose of BB-301 in December 2024 HAYWARD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing no

-Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been revised from the conference call information provided on October 12th- HAYWARD, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces updated webcast information to discuss the interim clinical study data previously reported on Saturday,

-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing- -Management plans to host a conference call on October 14 at 8:30 am EDT to discuss the interim results, details below- HAYWARD, Calif., Oct. 12, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform,

SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

SC 13D/A - Benitec Biopharma Inc. (0001808898) (Subject)

SC 13D - Benitec Biopharma Inc. (0001808898) (Subject)

SC 13G - Benitec Biopharma Inc. (0001808898) (Subject)

SC 13G - Benitec Biopharma Inc. (0001808898) (Subject)